Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 13, 2024
Reporting Period: Single event date (June 13, 2024)
This filing reports a regulatory milestone regarding the company's Nucynta franchise. Collegium Pharmaceutical, Inc. is an emerging growth company incorporated in Virginia.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event rather than financial performance data.
Material Changes
The material change reported is the U.S. Food and Drug Administration (FDA) granting pediatric exclusivity for the Nucynta franchise. This action extends the exclusivity period for the company's products:
- Nucynta: Exclusivity extended by six months to January 3, 2027.
- Nucynta ER: Exclusivity extended by six months to December 27, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the FDA decision. No specific financial guidance or forward-looking revenue projections are included in this text.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies, though the extension of exclusivity is a positive development intended to protect market share against generic competition.
Investor Verification Checklist
- Verify the exact expiration dates for Nucynta (January 3, 2027) and Nucynta ER (December 27, 2025) in the attached press release (Exhibit 99.1).
- Confirm the impact of the six-month extension on the company's projected cash flows and revenue runway for the Nucynta franchise.
- Review the company's most recent 10-Q or 10-K for current financial health metrics, as this 8-K does not contain them.